Importer of Controlled Substances Application: Caligor Coghlan Pharma Services, 53009-53010 [2022-18742]
Download as PDF
<![CDATA[
53009
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 167 / Tuesday, August 30, 2022 / Notices
VA; Vana Solutions, LLC., Beavercreek,
OH; VG IT Services, Inc., Ashburn, VA;
and W5 Technologies, Inc., Scottsdale,
AZ have been added as parties to this
venture.
Also, 1901 Group LLC, Reston, VA;
Alteryx, Inc., Irvine, CA; Aptima, Inc.,
Woburn, MA; Assured Wireless Corp.,
San Diego, CA; AT&T Government
Solutions, Inc., Vienna, VA; Broadband
Antenna Tracking Systems, Inc.,
Indianapolis, IN; Clemson University,
Clemson, SC; Decisive Analytics Corp.,
Arlington, VA; Dover Microsystems,
Inc., Waltham, MA; EPS Corp., Tinton
Falls, NJ; Global Planning Initiatives
LLC, Virginia Beach, VA;
HigherEchelon, Inc., Huntsville, AL;
Inonde, McLean, VA; IT Partners, Inc.,
Herndon, VA; KNC Strategic Services,
Oceanside, CA; Kopis Mobile LLC,
Flowood, MS; Kudu Dynamics LLC,
Chantilly, VA; L3Harris Technologies,
Palm Bay, FL; Lexington Solutions
Group LLC, Lexington, VA; Motorola
Solutions, Inc. US Federal Markets
Division, Linthicum, MD; NewSat North
America LLC, Indian Harbour Beach,
FL; Nobletech Solutions, Huntsville,
AL; Poplicus, Inc. dba Govini,
Arlington, VA; ProSync Technology
Group, Ellicott City, MD; Rincon
Research Corp., Tucson, AZ;
SafeFlights, Inc. dba 14bis Supply
Tracking, Burlington, MA; Shield AI,
Inc., San Diego, CA; Shift5, Inc.,
Rosslyn, VA; Si2 Technologies, Inc.,
North Billerica, MA; Southern
Methodist University, Dallas, TX; Streif
Enterprise, Inc. dba ibeeto, El Cajon, CA;
Taurean General Services, Boerne, TX;
XATOR Corp., Reston, VA; and XR 2
LEAD LLC, Dumfries VA have
withdrawn from this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and IWRP intends
to file additional written notifications
disclosing all changes in membership.
On October 15, 2018, IWRP filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on October 23, 2018 (83 FR 53499).
The last notification was filed with
the Department on April 6, 2022. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on May 13, 2022 (87 FR 29385).
Suzanne Morris,
Chief, Premerger and Division Statistics
Antitrust Division.
[FR Doc. 2022–18695 Filed 8–29–22; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
17:24 Aug 29, 2022
Jkt 256001
DEPARTMENT OF JUSTICE
Drug
code
Controlled substance
Schedule
Drug Enforcement Administration
Meperidine intermediate-C.
[Docket No. DEA–1061]
Bulk Manufacturer of Controlled
Substances Application: Purisys, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Purisys, LLC, has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to Supplementary
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 31, 2022. Such
persons may also file a written request
for a hearing on the application on or
before October 31, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on June 6, 2022, Purisys,
LLC, 1550 Olympic Drive, Athens,
Georgia 30601–1602, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
SUMMARY:
Controlled substance
Ibogaine ........................
5-Methyoxy-N,Ndiisopropyltryptamine.
Cocaine ........................
Ecgonine .......................
Meperidine ....................
Meperidine intermediate-A.
Meperidine intermediate-B.
PO 00000
Frm 00109
Fmt 4703
Drug
code
Schedule
7260
7439
I
I
9041
9180
9230
9232
II
II
II
II
9233
II
Sfmt 4703
9234
I
II
I
The company plans to bulk
manufacture the listed controlled
substances for the production of active
pharmaceutical ingredients (API) and
analytical reference standards for sale to
its customers. The company plans to
manufacture the above listed controlled
substances as clinical trial and starting
materials to make compounds for
distribution to its customers. No other
activities for these drug codes are
authorized for this registration.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–18739 Filed 8–29–22; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1069]
Importer of Controlled Substances
Application: Caligor Coghlan Pharma
Services
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Caligor Coghlan Pharma
Services has applied to be registered as
an importer of basic class(es) of
controlled substance(s). Refer to
Supplementary Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 29, 2022. Such
persons may also file a written request
for a hearing on the application on or
before September 29, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
SUMMARY:
E:\FR\FM\30AUN1.SGM
30AUN1
53010
Federal Register / Vol. 87, No. 167 / Tuesday, August 30, 2022 / Notices
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on June 1, 2022, Caligor
Coghlan Pharma Services, 1500
Business Park Drive, Unit B, Bastrop,
Texas 78602, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
Drug
code
Controlled substance
Lysergic acid
diethylamide.
Tapentadol ....................
I
Schedule
7315
I
9780
I II
The company plans to import the
listed controlled substances as finished
dosage units for use in clinical trials. No
other activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Kristi O’Malley,
Assistant Administrator.
Valor Review Board to consider
nominations for the 2021–2022 Medal of
Valor, and to make a limited number of
recommendations for submission to the
U.S. Attorney General to be cited.
Additional issues of importance to the
Board may also be discussed.
DATES: October 5, 2022, 12:30 p.m. to
3:00 p.m. EDT.
ADDRESSES: This meeting will be held
virtually using web conferencing
technology. The public may hear the
proceedings of this virtual meeting/
conference call by registering with
Gregory Joy at least seven (7) days in
advance with Gregory Joy (contact
information below).
FOR FURTHER INFORMATION CONTACT:
Gregory Joy, Policy Advisor, Bureau of
Justice Assistance, Office of Justice
Programs, by telephone at (202) 514–
1369, toll free (866) 859–2687, or by
email at Gregory.joy@usdoj.gov.
SUPPLEMENTARY INFORMATION: The
Public Safety Officer Medal of Valor
Review Board carries out those advisory
functions specified in 42 U.S.C. 15202.
Pursuant to 42 U.S.C. 15201, the
President of the United States is
authorized to award the Public Safety
Officer Medal of Valor, the highest
national award for valor by a public
safety officer.
This virtual meeting/conference call
is open to the public to participate
remotely. For security purposes,
members of the public who wish to
participate must register at least seven
(7) days in advance of the meeting/
conference call by contacting Mr. Joy.
Access to the virtual meeting/
conference call will not be allowed
without prior registration. Please submit
any comments or written statements for
consideration by the Review Board in
writing at least seven (7) days in
advance of the meeting date.
Gregory Joy,
Policy Advisor/Designated Federal Officer,
Bureau of Justice Assistance.
[FR Doc. 2022–18742 Filed 8–29–22; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2022–18710 Filed 8–29–22; 8:45 am]
BILLING CODE 4410–18–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
DEPARTMENT OF LABOR
[OJP (BJA) Docket No. 1805]
Employment and Training
Administration
khammond on DSKJM1Z7X2PROD with NOTICES
Meeting of the Public Safety Officer
Medal of Valor Review Board
Agency Information Collection for the
Employment and Training
Administration Quick Turnaround
Surveys; Comment Request
Office of Justice Programs
(OJP), Bureau of Justice Assistance
(BJA).
ACTION: Notice of meeting.
AGENCY:
This is an announcement of a
meeting (via WebEx/conference call-in)
of the Public Safety Officer Medal of
SUMMARY:
VerDate Sep<11>2014
17:24 Aug 29, 2022
Jkt 256001
ACTION:
Notice.
The Department of Labor’s
(DOL) Employment and Training
SUMMARY:
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
Administration (ETA) is soliciting
comments concerning a revision of a
currently approved collection for the
authority to conduct the information
collection request (ICR) titled,
‘‘Employment and Training
Administration Quick Turnaround
Surveys and Site Visits.’’ This comment
request is part of continuing
Departmental efforts to reduce
paperwork and respondent burden in
accordance with the Paperwork
Reduction Act of 1995 (PRA).
DATES: Consideration will be given to all
written comments received by October
31, 2022.
ADDRESSES: A copy of this ICR with
applicable supporting documentation,
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden,
may be obtained free by contacting
Charlotte Schifferes by telephone at
(202) 693–3655 (this is not a toll-free
number), TTY (202) 693–7755, (this is
not a toll-free number) or by email at
schifferes.charlotte@dol.gov.
Submit written comments about, or
requests for a copy of, this ICR by mail
or courier to the U.S. Department of
Labor, Employment and Training
Administration, Office of Policy
Development and Research, Attention:
Charlotte Schifferes, 200 Constitution
Avenue NW, Room N–5641,
Washington, DC 20210; by email:
schifferes.charlotte@dol.gov; or by Fax
(202) 693–2766.
FOR FURTHER INFORMATION CONTACT:
Charlotte Schifferes by telephone at
(202) 693–3655 (this is not a toll-free
number) or by email at
schifferes.charlotte@dol.gov.
SUPPLEMENTARY INFORMATION: DOL, as
part of continuing efforts to reduce
paperwork and respondent burden,
conducts a pre-clearance consultation
program to provide the general public
and federal agencies an opportunity to
comment on proposed and/or
continuing collections of information
before submitting them to the Office of
Management and Budget (OMB) for final
approval. This program helps to ensure
requested data can be provided in the
desired format, reporting burden (time
and financial resources) is minimized,
collection instruments are clearly
understood, and the impact of collection
requirements can be properly assessed.
ETA is soliciting comments regarding
a revision and extension of a currently
approved generic information
collection. The collection would allow
for a quick review process by OMB of
a series of 8 to 20 short surveys or site
visit protocols relevant to the broad
spectrum of programs administered by
E:\FR\FM\30AUN1.SGM
30AUN1
]]>Agencies
[Federal Register Volume 87, Number 167 (Tuesday, August 30, 2022)]
[Notices]
[Pages 53009-53010]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-18742]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1069]
Importer of Controlled Substances Application: Caligor Coghlan
Pharma Services
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Caligor Coghlan Pharma Services has applied to be registered
as an importer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
September 29, 2022. Such persons may also file a written request for a
hearing on the application on or before September 29, 2022.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If
[[Page 53010]]
you have received a Comment Tracking Number, your comment has been
successfully submitted and there is no need to resubmit the same
comment. All requests for a hearing must be sent to: (1) Drug
Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing should also be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on June 1, 2022, Caligor Coghlan Pharma Services, 1500
Business Park Drive, Unit B, Bastrop, Texas 78602, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide............. 7315 I
Tapentadol............................. 9780 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances as
finished dosage units for use in clinical trials. No other activities
for these drug codes are authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-18742 Filed 8-29-22; 8:45 am]
BILLING CODE 4410-09-P
